Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655281 | 0.94 | KLK7 (0.46) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5653518 | 0.94 | MAPT (0.46) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5653289 | 0.94 | KLK7 (0.45) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5655104 | 0.92 | KLK7 (0.44) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5655273 | 0.92 | CTSK (0.43) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5654714 | 0.92 | KLK7 (0.45) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5655177 | 0.92 | MAPT (0.44) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5653286 | 0.91 | KLK7 (0.43) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5655245 | 0.91 | KLK7 (0.44) | KLK7KLK5MAPTSIRT5CTSS | |
| SCHEMBL5653112 | 0.90 | KEAP1 (0.43) | KLK7KLK5MAPTSIRT5CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | KLK7 1738/4885KLK5 1984/4885MAPT 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.